Ann: Letter to Shareholders, page-2

A few key points whilst quickly reading;

. Our deal with Alodokter has the potential to see exponential growth in the use of ResAppDx as Alodokter connects over 50,000 doctors with millions of Indonesian patients.

Earlier this year we requested a Pre-Submission meeting with the FDA and, after a COVID-19-related delay, I’m pleased to confirm that we now have a meeting scheduled for December.

We are pleased with progress to date, having recently completed recruitment in India and will soon complete recruitment in the US.